Sagent Pharmaceuticals Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
233
- Latest Deal Type
-
PE Growth
- (Rumor/Speculation)
- Latest Deal Amount
-
$175M
Sagent Pharmaceuticals General Information
Description
Developer and manufacturer of injectable pharmaceuticals in North America. The company offers a broad range of products across anti-infective, oncology and critical care indications in a variety of presentations, including single and multi-dose vials and ready-to-use pre-filled syringes and premix bags, dedicated to fulfilling the evolving needs of patients and providers alike.
Contact Information
Website
www.sagentpharma.com(Operating Subsidiary)
Corporate Office
- 1515 East Woodfield Road
- Suite 1100
- Schaumburg, IL 60173
- United States
Corporate Office
- 1515 East Woodfield Road
- Suite 1100
- Schaumburg, IL 60173
- United States
Sagent Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. PE Growth/Expansion | 26-Mar-2025 | $175M | Rumor/Speculation | Profitable | ||
| 9. Merger/Acquisition | 28-Feb-2023 | Completed | Profitable | |||
| 8. Merger/Acquisition | 29-Aug-2016 | Completed | Profitable | |||
| 7. IPO | 19-Apr-2011 | Completed | Clinical Trials - General | |||
| 6. Early Stage VC (Series B1) | 01-Aug-2010 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B) | 01-Mar-2010 | Completed | Generating Revenue | |||
| 4. Debt - General | 30-Jun-2009 | Completed | Startup | |||
| 3. Early Stage VC (Series A) | 15-Jun-2009 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 01-Aug-2008 | $30M | $83M | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 01-Sep-2007 | $53M | $53M | Completed | Product Development |
Sagent Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | 113,000,000 | $0.000010 | $1 | $1 | 1x | $1 | 69.83% |
Sagent Pharmaceuticals Comparisons
Industry
Financing
Details
Sagent Pharmaceuticals Competitors (10)
One of Sagent Pharmaceuticals’s 10 competitors is Evonile Pharma, a Private Equity-Backed company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Glenmark Farmacêutica | Corporation | Sao Paulo, Brazil | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Dr. Reddy's | Corporation | Hyderabad, India | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria |
Sagent Pharmaceuticals Patents
Sagent Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20120000592-A1 | Label, labeling system and method of labeling for containers for drug products | Inactive | 01-Jul-2010 | ||
| WO-2012003453-A2 | Label, labeling system and method of labeling for containers for drug products | Inactive | 01-Jul-2010 | ||
| WO-2012003453-A3 | Label, labeling system and method of labeling for containers for drug products | Inactive | 01-Jul-2010 | ||
| US-20100017747-A1 | Product viewer | Inactive | 17-Jul-2008 | G06Q30/0603 |
Sagent Pharmaceuticals Signals
Sagent Pharmaceuticals Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CNF Investments | PE/Buyout | Minority | ||
| Capricorn Investment Group | Impact Investing | Minority | ||
| China Renaissance Capital Investment | Venture Capital | Minority | ||
| GrowthGate Capital | PE/Buyout | Minority | ||
| Morgan Stanley Investment Management | Asset Manager | Minority |
Sagent Pharmaceuticals Investments & Acquisitions (8)
Sagent Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Xellia Manufacturing Facility (Grove, Illinois). The deal was made on 01-Mar-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Xellia Manufacturing Facility (Grove, Illinois) | 01-Mar-2019 | Corporate Asset Purchase | Buildings and Property | ||
| Sagent Pharmaceuticals (Pharmaceutical Production Facility in Raleigh) | 01-Jan-2019 | Corporate Asset Purchase | Buildings and Property | ||
| SterRx | 21-Sep-2017 | Early Stage VC | Other Pharmaceuticals and Biotechnology | ||
| Teva Pharmaceutical Industries (Product Portfolio) | 16-Jun-2016 | Corporate Asset Purchase | Buildings and Property | ||
| Omega Laboratories (Drug Delivery) | 01-Oct-2014 | Merger/Acquisition | Drug Delivery |
Sagent Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Sagent Pharmaceuticals FAQs
-
When was Sagent Pharmaceuticals founded?
Sagent Pharmaceuticals was founded in 2006.
-
Where is Sagent Pharmaceuticals headquartered?
Sagent Pharmaceuticals is headquartered in Schaumburg, IL.
-
What is the size of Sagent Pharmaceuticals?
Sagent Pharmaceuticals has 233 total employees.
-
What industry is Sagent Pharmaceuticals in?
Sagent Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Sagent Pharmaceuticals a private or public company?
Sagent Pharmaceuticals is a Private company.
-
What is the current valuation of Sagent Pharmaceuticals?
The current valuation of Sagent Pharmaceuticals is .
-
What is Sagent Pharmaceuticals’s current revenue?
The current revenue for Sagent Pharmaceuticals is .
-
How much funding has Sagent Pharmaceuticals raised over time?
Sagent Pharmaceuticals has raised $251M.
-
Who are Sagent Pharmaceuticals’s investors?
CNF Investments, Capricorn Investment Group, China Renaissance Capital Investment, GrowthGate Capital, and Morgan Stanley Investment Management are 5 of 8 investors who have invested in Sagent Pharmaceuticals.
-
Who are Sagent Pharmaceuticals’s competitors?
Evonile Pharma, Glenmark Farmacêutica, Glenmark Pharmaceuticals, Dr. Reddy's, and Pfizer (Vienna) are some of the 10 competitors of Sagent Pharmaceuticals.
-
When was Sagent Pharmaceuticals acquired?
Sagent Pharmaceuticals was acquired on 26-Mar-2025.
-
Who acquired Sagent Pharmaceuticals?
Sagent Pharmaceuticals was acquired by Elliminist Singapore.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process